ACTBL2

Across TCGA pan-cancer cohorts, ACTBL2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ACTBL2 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ACTBL2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACTBL2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, COAD, and CCRCC are the cancer types where ACTBL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.298	0.708	.005	17	view →
COAD	DFS	Quartile	II,III,IV	0.838	1.000	.040	12	view →
CCRCC	DFS	Median	All	0.853	0.628	.004	7	view →
PDAC	DFS	Tertile	IV	0.203	0.752	.024	3	view →
LSCC	OS	Median	II,III,IV	0.885	1.000	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ACTBL2–LUAD (DFS)

Open the LUAD breakdown →